| Titre : | LE TRAITEMENT DE LA SURCHARGE EN FER CHEZ LES β THALASSEMIQUES | | Type de document : | thèse | | Auteurs : | NAJEM Salma, Auteur | | Année de publication : | 2023 | | Langues : | Français (fre) | | Mots-clés : | β Thalassémie Surcharge en fer Chélateurs Fer | | Résumé : | β Thalassemia is a chronic disease with multi-organ involvement and a complex and
burdensome treatment regimen. A comprehensive assessment of the disease burden requires
the study of a wide range of complications, both from the disease itself and from its treatment.
Iron overload remains the major challenge in the management of patients with β
thalassemia, although this has improved overall with advances in monitoring and the advent
of chelation therapy. Chelation is done either with the reference chelator, deferoxamine,
deferiprone or deferasirox but also in combination. Recently, it can be accompanied by
preventive therapies such as minihepcidines.
Nevertheless, contemporary studies continue to illustrate a gap between the life
expectancy of patients with β-thalassemia and the general population. This is due to barriers
to adherence to iron chelators including patient-related barriers and adverse effects of
treatment. The pharmacist is a key player in managing these gaps and finding new, less
burdensome therapeutic solutions. | | Numéro (Thèse ou Mémoire) : | P0302023 | | Président : | Yassir BOUSLIMAN | | Directeur : | Mina AIT EL CADI | | Juge : | Mustapha BOUATIA | | Juge : | Yasmina TADLAOUI | | Juge : | Samira SERRAGUI |
LE TRAITEMENT DE LA SURCHARGE EN FER CHEZ LES β THALASSEMIQUES [thèse] / NAJEM Salma, Auteur . - 2023. Langues : Français ( fre) | Mots-clés : | β Thalassémie Surcharge en fer Chélateurs Fer | | Résumé : | β Thalassemia is a chronic disease with multi-organ involvement and a complex and
burdensome treatment regimen. A comprehensive assessment of the disease burden requires
the study of a wide range of complications, both from the disease itself and from its treatment.
Iron overload remains the major challenge in the management of patients with β
thalassemia, although this has improved overall with advances in monitoring and the advent
of chelation therapy. Chelation is done either with the reference chelator, deferoxamine,
deferiprone or deferasirox but also in combination. Recently, it can be accompanied by
preventive therapies such as minihepcidines.
Nevertheless, contemporary studies continue to illustrate a gap between the life
expectancy of patients with β-thalassemia and the general population. This is due to barriers
to adherence to iron chelators including patient-related barriers and adverse effects of
treatment. The pharmacist is a key player in managing these gaps and finding new, less
burdensome therapeutic solutions. | | Numéro (Thèse ou Mémoire) : | P0302023 | | Président : | Yassir BOUSLIMAN | | Directeur : | Mina AIT EL CADI | | Juge : | Mustapha BOUATIA | | Juge : | Yasmina TADLAOUI | | Juge : | Samira SERRAGUI |
|
Accueil
Affiner la recherche Faire une suggestionLE TRAITEMENT DE LA SURCHARGE EN FER CHEZ LES β THALASSEMIQUES / NAJEM Salma
